Evidence map›Paper›PMID 37231494›Full record

ArticleRetrovirology2023

Reduced CCR5 expression among Uganda HIV controllers.

Brian Nyiro, Sharon Bright Amanya, Alice Bayiyana, Francis Wasswa, Eva Nabulime, Alex Kayongo, Immaculate Nankya, Gerald Mboowa, David Patrick Kateete, Obondo James Sande

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. HIV controllers: hope for a functional cure.Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Brian NyiroNew Jersey Medical School, Rutgers University, New Jersey, USA.
Sharon Bright AmanyaBaylor College of Medicine, Houston, TX, USA.
Alice BayiyanaDepartment of Immunology and Molecular Biology, Makerere University, Kampala, Uganda.
Francis WasswaDepartment of Immunology and Molecular Biology, Makerere University, Kampala, Uganda.
Eva NabulimeCentre for AIDS Research Laboratory, Joint Clinical Research Centre, Wakiso, Uganda.
Alex KayongoDepartment of Immunology and Molecular Biology, Makerere University, Kampala, Uganda.
Immaculate NankyaCentre for AIDS Research Laboratory, Joint Clinical Research Centre, Wakiso, Uganda.
Gerald MboowaDepartment of Immunology and Molecular Biology, Makerere University, Kampala, Uganda.
David Patrick KateeteDepartment of Immunology and Molecular Biology, Makerere University, Kampala, Uganda.
Obondo James SandeDepartment of Immunology and Molecular Biology, Makerere University, Kampala, Uganda. ojsande@gmail.com.
Makerere University · UGJoint Clinical Research Centre · UGBaylor College of Medicine · USRutgers, The State University of New Jersey · US

Funding

Microbiology and Immunology Training for HIV and HIV-Related Research in Uganda (MITHU)D43TW010319 · FIC · CASE WESTERN RESERVE UNIVERSITY · PI BOOM, W. HENRY, JOLOBA, MOSES LUTAAKOME · 2016 to 2025
$3.1M
Investigating the role of altered lung microbiome in fueling Th17 mediated airway inflammation in COPD among HIV-infected individualR21TW012354 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI KAYONGO, ALEX · 2022 to 2023
$573k
FIC NIH HHS D43 TW010319FIC NIH HHS R21 TW012354
6 · The paper itself

Abstract

backgroundSeveral mechanisms including reduced CCR5 expression, protective HLA, viral restriction factors, broadly neutralizing antibodies, and more efficient T-cell responses, have been reported to account for HIV control among HIV controllers. However, no one mechanism universally accounts for HIV control among all controllers. In this study we determined whether reduced CCR5 expression accounts for HIV control among Ugandan HIV controllers. We determined CCR5 expression among Ugandan HIV controllers compared with treated HIV non-controllers through ex-vivo characterization of CD4 + T cells isolated from archived PBMCs collected from the two distinct groups.

resultsThe percentage of CCR5 + CD4 + T cells was similar between HIV controllers and treated HIV non-controllers (ECs vs. NCs, P = 0.6010; VCs vs. NCs, P = 0.0702) but T cells from controllers had significantly reduced CCR5 expression on their cell surface (ECs vs. NCs, P = 0.0210; VCs vs. NCs, P = 0.0312). Furthermore, we identified rs1799987 SNP among a subset of HIV controllers, a mutation previously reported to reduce CCR5 expression. In stark contrast, we identified the rs41469351 SNP to be common among HIV non-controllers. This SNP has previously been shown to be associated with increased perinatal HIV transmission, vaginal shedding of HIV-infected cells and increased risk of death.

conclusionCCR5 has a non-redundant role in HIV control among Ugandan HIV controllers. HIV controllers maintain high CD4 + T cells despite being ART naïve partly because their CD4 + T cells have significantly reduced CCR5 densities.

Indexed as

HIV-1HIV InfectionsCD4-Positive T-LymphocytesFemaleHIV Non-ProgressorsHumansReceptors, CCR5UgandaCCR5 protein, humanReceptors, CCR5CCR5 promoter polymorphismsElite controllersHIVNon-controllersViremic controllers

Identifiers

PMID37231494
PMCPMC10210444
OpenAlexW4378227154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.